{"title":"Bioabsorbable spacer-assisted high-dose proton beam therapy for unresectable locally advanced pancreatic cancer of the body or tail: a feasibility and safety study.","authors":"Hiroyuki Nakamura, Yoshihide Nanno, Kazuki Terashima, Yoshiro Matsuo, Daiki Takahashi, Yasue Niwa, Yusuke Demizu, Sunao Tokumaru, Tomoaki Okimoto, Ryohei Sasaki, Shohei Komatsu","doi":"10.1016/j.radonc.2026.111872","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111872","url":null,"abstract":"<p><strong>Background and purpose: </strong>Anatomical proximity to gastrointestinal (GI) organs can preclude dose-escalated irradiation for locally advanced pancreatic cancer (LAPC). We evaluated the safety and feasibility of bioabsorbable spacer-assisted high-dose proton beam therapy (PBT) for unresectable LAPC of the pancreatic body or tail.</p><p><strong>Materials and methods: </strong>This exploratory retrospective analysis used retrospectively reviewed perioperative data and retrospectively or prospectively collected PBT data. Fourteen patients with presumed nonmetastatic LAPC underwent placement of a bioabsorbable polyglycolic acid (PGA) spacer. Thirteen received definitive PBT at 67.5 or 75 Gy (relative biological effectiveness [RBE]) in 25 fractions. The composite primary safety endpoint was the occurrence of a Clavien-Dindo grade ≥III surgical complication or a CTCAE grade ≥3 adverse event related to definitive PBT or concurrent chemotherapy.</p><p><strong>Results: </strong>Spacer placement achieved ≥10 mm tumor-GI separation in all 14 patients; 13 completed definitive PBT. No Clavien-Dindo grade ≥III surgical complication occurred. Four of 13 definitive-PBT patients (30.8%) experienced at least one qualifying safety event: one experienced grade 3 nausea and three other patients experienced grade 3 leukopenia/neutropenia. No grade ≥3 structural GI injury was observed. Median follow-up was 19.3 months. Median overall and progression-free survival were 24.8 and 11.8 months, respectively; 1- and 2-year local control rates were 81.5% and 38.2%.</p><p><strong>Conclusion: </strong>Bioabsorbable spacer-assisted high-dose PBT was technically feasible in this selected cohort. However, this small, uncontrolled study cannot establish a low risk of uncommon or late adverse events or support conclusions regarding comparative safety or efficacy.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111872"},"PeriodicalIF":5.8,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Phase I dose-escalation study of stereotactic body radiotherapy with elective nodal irradiation for borderline resectable and unresectable locally advanced pancreatic cancer.","authors":"Rei Umezawa, Masamichi Mizuma, Kei Nakagawa, Yoshiyuki Katsuta, Shohei Tanaka, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Hinako Harada, Noriyuki Kadoya, Michiaki Unno, Keiichi Jingu","doi":"10.1016/j.radonc.2026.111871","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111871","url":null,"abstract":"<p><strong>Background: </strong>Locoregional recurrence remains a major clinical challenge in borderline resectable (BR) and unresectable locally advanced (UR-LA) pancreatic cancer, even after stereotactic body radiotherapy (SBRT). This phase I trial evaluated the safety, maximum tolerated dose (MTD), and preliminary efficacy of adding prophylactic elective nodal irradiation (ENI) to 5-fraction SBRT.</p><p><strong>Methods: </strong>Patients with BR/UR-LAPC were enrolled in a 3 + 3 dose-escalation design. SBRT was delivered in 5 fractions using either adaptive magnetic resonance image-guided radiation therapy or respiratory breath-hold radiotherapy with a fiducial marker. The ENI dose was fixed at 30 Gy in five fractions, while the primary tumor dose increased from Level 1 (35 Gy) to Level 3 (40 Gy). The primary endpoint was acute dose-limiting toxicity (DLT) (any Grade ≥ 3 non-hematological adverse events within 14 days after the completion of SBRT).</p><p><strong>Results: </strong>Twelve patients (BR: 4, LA: 8) were enrolled, 11 of whom had previously received systemic chemotherapy. One patient at Level 1 experienced acute Grade 3 anorexia/nausea requiring hospitalization. No DLTs were observed at Levels 2 and 3, and the MTD was not reached. Three patients with preexisting biliary stents developed subacute Grade 3 cholangitis. No Grade ≥ 3 late adverse events occurred. The median overall survival after SBRT was 17.3 months, and the 1-year locoregional control rate was 75%.</p><p><strong>Conclusion: </strong>Five-fraction SBRT with simultaneous 30 Gy ENI was feasible, and the MTD was not reached within the tested dose levels up to 40 Gy. Further prospective studies are needed to evaluate its long-term safety and treatment outcomes.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111871"},"PeriodicalIF":5.8,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julia Bauer, Tanja Adena-Eichkorn, Lia Velkova, Jürgen Debus, Laila König, Semi Harrabi
{"title":"Independent validation of a predictive risk model for contrast-enhancing brain lesions supports enhanced periventricular radiosensitivity and variable proton RBE.","authors":"Julia Bauer, Tanja Adena-Eichkorn, Lia Velkova, Jürgen Debus, Laila König, Semi Harrabi","doi":"10.1016/j.radonc.2026.111873","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111873","url":null,"abstract":"<p><strong>Background and purpose: </strong>Contrast-enhancing brain lesions (CEBLs) were reported as MR-imaging (MRI) endpoint to assess dose effects in healthy brain tissue following proton radiotherapy (PRT) of low-grade-glioma (LGG) patients. A voxel-level risk model was proposed with absorbed dose (D), dose-averaged linear energy transfer (LET<sub>D</sub>), and proximity to the ventricular system as risk factors. We validated this model in an independent LGG patient cohort.</p><p><strong>Material and methods: </strong>LGG patients treated at the same institution but more recently (2015-2019) were considered. For each patient, follow-up MRI data were screened for CEBLs, complication-risk maps were calculated and patient-level NTCP<sub>CEBL</sub> values were determined according to the original model. Eventually, risk model coefficients were updated by regressing the original logistic model to the validation cohort (validC) data.</p><p><strong>Results: </strong>The validC comprised 112 subjects. Observed CEBL incidence of 21% was the same as in the modelling cohort (modelC); observed number of CEBLs and median lesion volume were considerably smaller in the validC, (N<sub>validC</sub> = 26, N<sub>modelC</sub> = 67 and V<sub>med,validC</sub> = 110 mm<sup>3</sup>, V<sub>med,modelC</sub> = 235 mm<sup>3</sup>). Good calibration of the original patient-level NTCP<sub>CEBL</sub> model was obtained in the validC. Update of the model coefficients yielded a more pronounced LET<sub>D</sub>-effect and a 2.4 times higher odds ratio for the complication risk in the periventricular space (PVS).</p><p><strong>Conclusions: </strong>The presented validation confirms an enhanced radiosensitivity of the PVS, a variable proton RBE, and supports serial complication characteristics of the brain. This underlines the need for a PRT strategy that actively spares the PVS under consideration of an LET<sub>D</sub>-dependent proton RBE.</p><p><strong>Clinical trial information: </strong>The study was approved by the ethics committee of the Heidelberg University Hospital (ethics vote: S-516/2022).</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111873"},"PeriodicalIF":5.8,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarmini Bavananthan, Morgane Dos Santos, Georges Tarlet, Karen Chaaya, Charline Jouannet, Mohammed Amine Benadjaoud, Nicolas Verger, Samia Boussouar, Laurène Lyvia Jean-Joseph, Valérie Buard, Olivier Guipaud, Vincent Paget, Fabien Milliat, Agnès François
{"title":"Impact of chemical depletion of club cells on the pulmonary response to irradiation in mice.","authors":"Sarmini Bavananthan, Morgane Dos Santos, Georges Tarlet, Karen Chaaya, Charline Jouannet, Mohammed Amine Benadjaoud, Nicolas Verger, Samia Boussouar, Laurène Lyvia Jean-Joseph, Valérie Buard, Olivier Guipaud, Vincent Paget, Fabien Milliat, Agnès François","doi":"10.1016/j.radonc.2026.111866","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111866","url":null,"abstract":"<p><strong>Introduction: </strong>Radiation-induced acute pneumopathy and lung fibrosis are debilitating clinical conditions that may occur following radiation therapy to the chest area. As opposed to alveolar compartment, the response of the bronchiolic epithelium and its role in tissue damage have been only sparsely addressed. Club cells reside in the bronchiolic epithelium and sustain epithelial integrity and response to trauma. Our aim was to investigate the role of club cells in radiation-induced lung damage.</p><p><strong>Materials and methods: </strong>We used two preclinical models of X-ray radiation lung damage in mice: a model of whole thorax irradiation to 20 Gy and an accurate model irradiating 4% of the mouse lung to 80 Gy. Naphthalene-induced depletion of club cells was induced prior to irradiation and tissue damage followed by microCT analyses, histology, immunohistology and single cell RNA sequencing 1 and 6 months post-exposure.</p><p><strong>Results: </strong>Exposing the whole thorax in absence of club cells resulted in severe animal mortality compared to controls. In case of small volume exposure, tentative of epithelial regeneration is observed via stem cells mobilization in the severely injured area, most likely from the margins. In absence of club cells, possible stem cells' exhaustion in response to cell depletion compromised their mobilization from the margins and may be responsible for tissue damage extension. Analyses in single cell RNA sequencing revealed interesting features of lung response to focal irradiation with increased endothelial-to-mesenchymal profile, broncho-alveolar stem cells mobilization and early foamy macrophages involvement in NA-treated tissues.</p><p><strong>Conclusion: </strong>Our data suggest a delay in regeneration processes when the lung is irradiated in absence of club cells. This raises interest in studying these cells in future research on the response of the healthy lungs to radiation exposure. We also may point out that pre-existing clinical conditions associated with club cell loss might be at risk for developing radiotherapy-related side effects in patients treated for thoracic tumors.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111866"},"PeriodicalIF":5.8,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149410178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F De Felice, S Pedretti, I Palumbo, Y Atagun, M C De Santis, M Krengli, I Ratosa, C E Coles, M Arenas, L J Boersma, F Marazzi, I Meattini, P Poortmans, C Aristei, B Offersen, O Kaidar-Person
{"title":"Navigating treatment for De novo oligometastatic breast cancer: The Assisi think tank meeting.","authors":"F De Felice, S Pedretti, I Palumbo, Y Atagun, M C De Santis, M Krengli, I Ratosa, C E Coles, M Arenas, L J Boersma, F Marazzi, I Meattini, P Poortmans, C Aristei, B Offersen, O Kaidar-Person","doi":"10.1016/j.radonc.2026.111869","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111869","url":null,"abstract":"<p><p>The 2026 Assisi Think Tank Meeting, in collaboration with EUSOMA, ESTRO, and AIRO, identified de novo oligometastatic breast cancer (dnOMBC) as a clinically relevant challenge. A comprehensive review of 39 publications highlights a significant heterogeneity in locoregional treatment strategies, including varying approaches to surgical and radiation oncology management for both the primary tumour as for the metastases. The overall level of evidence is low, with only one trial, MF07-01, demonstrating a clear benefit in terms of overall survival. Therefore, we recommend applying the Advanced Breast Cancer (ABC) guidelines, considering locoregional interventions after a 3-8 months induction of systemic therapy to facilitate identification of patients with better outcomes. On longer term perspective, our findings emphasise the need for obtaining more results from ongoing and future prospective clinical trials to define the optimal role of local therapies, including surgery and radiation therapy, in improving patient outcomes. For this, we encourage a proper application of biologically driven paradigms, using advanced imaging and biomarker monitoring to better identify true oligometastatic disease, as well as to optimise outcomes by combining locoregional treatments with immunotherapy.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111869"},"PeriodicalIF":5.8,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149410179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Particle therapy for T3N0M0 non-small cell lung cancer: a Japanese nationwide prospective registry study.","authors":"Masaki Nakamura, Nobuteru Kubo, Kazushi Maruo, Masao Murakami, Hiromitsu Iwata, Sunao Tokumaru, Takahiro Waki, Genki Adachi, Kimihiro Shimizu, Yasushi Goto, Takayuki Hashimoto, Hitoshi Ishikawa, Hiroaki Suefuji, Hideyuki Harada, Yoshiyuki Shioyama","doi":"10.1016/j.radonc.2026.111865","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111865","url":null,"abstract":"<p><strong>Purpose: </strong>Particle therapy offers dosimetric advantages over conventional photon therapy, potentially minimizing toxicities for larger tumors. This study evaluated the clinical outcomes and safety of particle therapy for cT3N0M0 non-small cell lung cancer (NSCLC) using a Japanese nationwide prospective registry.</p><p><strong>Methods: </strong>This multicenter prospective observational registry study included patients with cT3N0M0 NSCLC who were treated with proton beam therapy or carbon-ion radiotherapy between May 2016 and June 2021. Overall survival (OS), progression-free survival (PFS), cumulative incidence of local failure (LF), and adverse events were evaluated. Prognostic factors were compared using the Cox proportional hazards model and the cumulative incidence curves were compared using the Fine-Gray model.</p><p><strong>Results: </strong>A total of 96 patients were evaluated. With a median follow-up of 53 months, the 3-year OS, PFS, and LF rates were 48.1 %, 33.0 %, and 19.2 %, respectively. Grade 3 or higher adverse events were observed in 5 patients (5.2 %), with no Grade 5 events reported. In multivariate analysis, concomitant interstitial lung disease and low vital capacity were identified as significant prognostic factors for both OS and PFS. No statistically significant associations with OS or PFS were detected for tumor size > 5 cm, treatment modality, or chemotherapy.</p><p><strong>Conclusion: </strong>Particle therapy showed encouraging survival outcomes and a low reported incidence of severe toxicity in patients with cT3N0M0 NSCLC, potentially offering a definitive treatment option for those who are medically inoperable or decline surgery.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111865"},"PeriodicalIF":5.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149410180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Darren Mc Poon, Kenneth Cw Wong, Daisy Cm Lam, Cheuk-Fun Chan, Allen Cc Chen, David Johnson, Benjamin Hw Lam, Matthew Mp Lee, Landon L Chan, Clement Cm Chu, C F Ng, Frankie Kf Mo, Anthony Tc Chan, Tony Mok
{"title":"Toxicity and patient-reported quality of life through 12 months following pelvis-inclusive once-weekly stereotactic body radiotherapy versus conventional IMRT for high-risk prostate cancer: updated results of the SRAM randomized phase II trial.","authors":"Darren Mc Poon, Kenneth Cw Wong, Daisy Cm Lam, Cheuk-Fun Chan, Allen Cc Chen, David Johnson, Benjamin Hw Lam, Matthew Mp Lee, Landon L Chan, Clement Cm Chu, C F Ng, Frankie Kf Mo, Anthony Tc Chan, Tony Mok","doi":"10.1016/j.radonc.2026.111870","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111870","url":null,"abstract":"<p><strong>Aim: </strong>To compare toxicity through 12 months and patient-reported quality of life following pelvis-inclusive stereotactic body radiotherapy (SBRT) versus conventional intensity-modulated radiotherapy (IMRT) in men with high-risk prostate cancer enrolled in the SRAM trial (NCT03938649).</p><p><strong>Methods: </strong>Men with node-negative high-risk prostate cancer were randomly assigned 1:1 to pelvis-inclusive SBRT or IMRT. SBRT was delivered 40 Gy to the prostate and 25 Gy to the pelvis in five once-weekly fractions; IMRT comprised 50 Gy to the prostate and pelvis followed by a 26 Gy prostate boost. Gastrointestinal (GI) and genitourinary (GU) toxicities were graded using Common Terminology Criteria for Adverse Events version 4.0. Patient-reported outcomes were assessed using the Expanded Prostate Cancer Index (EPIC) and International Prostate Symptom Score (IPSS).</p><p><strong>Results: </strong>Among 121 evaluable patients, 60 received SBRT and 61 IMRT. Between 6 and 12 months after radiotherapy, grade ≥2 GI and GU toxicity occurred in 16.7 % versus 13.1 % (p = 0.583) and 11.7 % versus 16.4 % (p = 0.455) of patients, respectively, including one grade 3 rectal hemorrhage after SBRT. EPIC bowel scores were lower in the SBRT group at 9 months (83.2 vs. 92.4; p = 0.0022) and 12 months (82.5 vs. 90.1; p = 0.0181), reflecting greater declines from baseline. Other EPIC domains and IPSS outcomes were broadly similar between groups.</p><p><strong>Conclusion: </strong>Once-weekly pelvis-inclusive SBRT showed no significant difference in grade ≥2 GI and GU toxicity compared with conventional IMRT at 6-12 months, but was associated with worse patient-reported bowel quality of life at 9-12 months.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111870"},"PeriodicalIF":5.8,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic value of lymph node ratio beyond extranodal extension in node-positive oral cavity squamous cell carcinoma.","authors":"Anuj Kumar, Sarbani Ghosh Laskar, Prashasti Sharma, Shwetabh Sinha, Samarpita Mohanty, Ashwini Budrukkar, Monali Swain, Gouri Pantvaidya, Deepa Nair, Shivakumar Thiagarajan, Chandrashekhar Dravid, Vidisha Tuljapurkar, Anuja Deshmukh, Richa Vaish, Rukmini Prabhu, Sudhir Nair, Poonam Joshi, Arjun Singh, Kumar Prabhash, Vanita Noronha, Amit Joshi, Nandini Menon, Minit Shah, Aditya Dhanawat, Pankaj Chaturvedi","doi":"10.1016/j.radonc.2026.111863","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111863","url":null,"abstract":"<p><strong>Purpose: </strong>Extranodal extension (ENE) is a key determinant of adjuvant therapy in node-positive oral cavity squamous cell carcinoma (OCSCC). However, conventional nodal staging may not fully capture the quantitative burden of nodal disease. We evaluated whether lymph node ratio (LNR) provides additional prognostic value beyond ENE in a large randomized trial cohort.</p><p><strong>Methods and materials: </strong>We performed a retrospective subgroup analysis of 661 node-positive patients from the phase III randomized Oral Cavity Adjuvant Therapy (OCAT) trial. LNR was defined as the metastatic-to-dissected lymph node ratio and categorized as low (<0.10) or high (≥0.10). Overall survival (OS), recurrence-free survival (RFS), and locoregional control (LRC) were estimated using Kaplan-Meier and Cox regression, adjusting for ENE, T stage, N stage, PNI, margin status, LVI, and treatment arm.</p><p><strong>Results: </strong>With a median follow-up of 91 months, 387 deaths occurred. On multivariable analysis, high LNR remained independently associated with inferior OS (HR 1.43, 95% CI 1.15-1.78; p = 0.001), RFS (HR 1.48; p = 0.001), and LRC (HR 1.40; p = 0.018). High LNR/ENE-positive patients had significantly worse survival than the reference group, low LNR/ENE-negative (HR 2.08, 95% CI 1.47-2.95; p < 0.001). Low LNR/ENE-positive patients trended toward inferior survival (HR 1.36; p = 0.051), while high LNR/ENE-negative patients showed no significant difference (HR 1.12; p = 0.65).</p><p><strong>Conclusions: </strong>LNR is an independent prognostic factor beyond ENE across OS, RFS, and LRC in node-positive OCSCC. High LNR combined with ENE identifies a distinctly high-risk subgroup, whereas high LNR alone did not significantly impact survival in the absence of ENE. Incorporating LNR into postoperative risk stratification may refine identification of patients for risk-adapted adjuvant strategies.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111863"},"PeriodicalIF":5.8,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149387582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jerusha Padayachee, Noelia Sanmamed, Xiang Y Ye, Zhihui Amy Liu, Jenny Lee, Alejandro Berlin, Tim Craig, Bernadeth Lao, Alexandra Rink, Andrew Bayley, Charles Catton, Warren Foltz, Andrew McPartlin, Sangeet Ghai, Rachel M Glicksman, Mary Gospodarowicz, Padraig Warde, Cynthia Ménard, Peter Chung
{"title":"MRI-guided HDR brachytherapy or integrated VMAT boost for tumour-targeted dose escalation in localised prostate cancer: long-term results of the TARGET study.","authors":"Jerusha Padayachee, Noelia Sanmamed, Xiang Y Ye, Zhihui Amy Liu, Jenny Lee, Alejandro Berlin, Tim Craig, Bernadeth Lao, Alexandra Rink, Andrew Bayley, Charles Catton, Warren Foltz, Andrew McPartlin, Sangeet Ghai, Rachel M Glicksman, Mary Gospodarowicz, Padraig Warde, Cynthia Ménard, Peter Chung","doi":"10.1016/j.radonc.2026.111853","DOIUrl":"10.1016/j.radonc.2026.111853","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate local control of the gross tumour volume in localised prostate cancer following focal dose escalation delivered by integrated boost volumetric modulated arc therapy (IB-VMAT) or high-dose-rate (HDR) brachytherapy.</p><p><strong>Materials and methods: </strong>Patients with localised prostate cancer and an intraprostatic lesion identified on multiparametric magnetic resonance imaging (mpMRI) were included in a prospective, non-randomised phase II study. Eighty patients received VMAT to the prostate 76 Gy/38 fractions. Boost strategy involved an IB of 95 Gy/38 fractions (IB-VMAT) or a single fraction of 10 Gy (HDR-VMAT). Three patients received 6 months androgen deprivation therapy. The primary endpoint was 3-year local control (LC) assessed by MRI or MRI-guided biopsy. Secondary outcomes included biochemical failure-free survival (bFFS), toxicity and health-related quality of life (HRQoL), assessed using CTCAE v.4.0, the American Urological Association Symptom Score and EPIC.</p><p><strong>Results: </strong>Median follow-up was 4.8 years (IQR, 4.0-8.0). Sixty-six patients underwent a 3-year MRI or MRI-guided biopsy; one patient demonstrated recurrence within the boost volume. Four patients demonstrated intraprostatic failure outside the boost volume and three patients developed regional/distant metastases. Eight patients experienced biochemical failure (4 IB-VMAT; 4 HDR-VMAT). Overall, 5-year bFFS was 86.9% (95% CI, 79.1-95.5). No substantial differences in late toxicities and HRQoL were observed between cohorts.</p><p><strong>Conclusion: </strong>Intraprostatic tumour-targeted dose escalation using IB-VMAT or HDR-VMAT provided high rates of LC and bFFS with limited adverse impact in late toxicity and HRQoL. Randomised studies are needed to further define the merits and differences between the two techniques.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111853"},"PeriodicalIF":5.8,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Josiane Menard, Amélie Lusque, Justine Attal, Théo Carrié, Charlotte Chollet, Alexandra Martinez, Sarah Bétrian, Martine Delannes, Anne Ducassou
{"title":"Impact of sexological follow-up on the sexual function of patients treated with chemo-radiotherapy and brachytherapy for locally advanced cervical cancer: results of the prospective FEMINICOL study.","authors":"Josiane Menard, Amélie Lusque, Justine Attal, Théo Carrié, Charlotte Chollet, Alexandra Martinez, Sarah Bétrian, Martine Delannes, Anne Ducassou","doi":"10.1016/j.radonc.2026.111861","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111861","url":null,"abstract":"<p><strong>Background and purpose: </strong>Radiotherapy and brachytherapy (BT) for locally advanced cervical cancer (LACC) are associated with high rates of sexual morbidity, particularly vaginal stenosis. The prospective FEMINICOL study assessed sexual function and vaginal toxicity in patients treated with chemoradiotherapy (CRT) and image-guided adaptive BT, with systematic sexological support.</p><p><strong>Materials and methods: </strong>This single-centre prospective cohort study (NCT03956498) included patients treated with concomitant CRT and BT between October 2019 and December 2020. A certified sex therapist met each patient before BT, at 2 months and 1 year after treatment. The primary objective was to evaluate sexual function one year after treatment using the FSFI questionnaire.</p><p><strong>Results: </strong>Sixty patients were included in the study. Among patients who received clinical follow-up (54 at 2 months and 47 at 1 year), compliance with sexological follow-up was 98.1 % (53/54) at two months and 100 % at one year. Fifty-six patients with baseline evaluation and at least one post-treatment evaluation were analyzed. Median age was 54.5 years (31-77). At one year, 55.3 % of patients adhered to vaginal rehabilitation and 45.7 % were sexually active. Median FSFI score improved from 4 (range: 2-33.2) at baseline to 12.5 (2-34.8) at 1 year (paired test p < 0.001). Median sexual activity (QLQ-CX24) increased from 0 (0-66.7) to 33.3 (0-100) at 1 year (p < 0.001), while sexual anxiety remained stable (p = 0.93). At 1 year, Grade ≥ 3 vaginal toxicity occurred in 12.7 % of patients, mainly narrowing (8.5 %). Most patients (81.4 %) were satisfied with the sexological support.</p><p><strong>Conclusion: </strong>In this prospective cohort, systematic sexological support during and after CRT and BT was feasible and was associated with encouraging compliance with vaginal rehabilitation and favorable sexual function outcomes over time.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111861"},"PeriodicalIF":5.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}